You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.
-
OPTIMIZATION AND ASSESSMENT OF A BIOLOGIC TO IMPROVE FUNCTIONAL RECOVERY AFTER PERIPHERAL NERVE INJURY
SBC: Alcamena Stem cell Therapeutics, LLC Topic: NINDSABSTRACT. Peripheral nerve injury (PNI) is a common and challenging clinical problem affecting over 3% of U.S. trauma patients. Among combat trauma, the rate of PNI increases to 22%. These patients require extensive resources for initial treatment and therapy, yet they are still left with functional disability. Current treatments for motor, sensory, and mixed PNI include nerve autografts and axona ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Intelligent Biometrics to Optimize Prolonged Exposure Treatment for PTSD (IB-PE)
SBC: Zeriscope, Inc. Topic: 104PROJECT SUMMARY/ABSTRACT Posttraumatic Stress Disorder (PTSD) is a debilitating disease affecting millions of American military veterans and civilians. Prolonged Exposure (PE) therapy is evidence-based and effective but limited by high dropout rates and incomplete resolution of symptoms in approximately one-third of patients. A crucial component of PE, as well as interventions for anxiety disorder ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
A Novel Probiotic Engineered for Enhanced Immunological Function for Treating Inflammatory Bowel Disease
SBC: Rise Therapeutics, LLC Topic: NIAIDProject Summary The goal of this project is to commercialize a novel, immunologically-enhanced version of Lactobacillus acidophilus for the treatment of inflammatory bowel disease (IBD). Over 1.6 million adults and children in the United States suffer from IBD, an umbrella term encompassing two chronic inflammatory diseases of the gastrointestinal tract: Crohnandapos;s disease (CD) and ulcerative ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Development of streamlined chemoenzymatic glycan remodeling systems for antibodies and other important glycoproteins
SBC: Glycot Therapeutics, LLC Topic: 300Project abstract/summary This proposal responds to the NIH PA-16-157 “New Technologies for the Glycosciences (R43/R44)”. We aim to develop efficient and streamlined cheomoenzymatic systems for glycan remodeling of antibodies and other important glycoproteins, through optimizing enzyme immobilization and simplifying the reaction procedures. Such immobilized enzymes, when combined with activated ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Monoclonal antibodies targeting novel sites of vulnerability in marburg virus glycoprotein
SBC: Integrated Biotherapeutics, Inc. Topic: NIAIDFiloviruses, consisting of two major virus families including the ebolaviruses and marburgviruses (MARV and RAVV), cause periodic outbreaks of severe viral hemorrhagic fever with mortality rates as high as 90%. Since it is difficult to predict the species that would dominate future outbreaks, development of broadly protective therapeutics to prevent and manage future filovirus outbreaks is of high ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Custom-Fit Personal Sound Amplification Smartphone Application
SBC: ASCENDING HEARING TECHNOLOGIES, LLC Topic: NIDCDPROJECT SUMMARYPersonal sound amplification productsPSAPshave recently become available to the publicPSAPs serve a potentially important role in providing audibility of sounds for adults who have difficulty hearing in some daily living situationsbut may not be candidates for traditionalhigh amplification hearing aidsFewer thanof adults with hearing loss reporting use of hearing aidsciting high cos ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
A novel asthma drug candidate targeting the GABAergic system in lung inflammation
SBC: PANTHERICS INCORPORATED Topic: NHLBIThe proposed research will advance preclinical characterization and validation of a novel drug for asthmaA growing body of research has uncovered functional gamma amino butyric acid type A receptorGABAARsignaling in non neuronal cellsOur research has demonstrated that ligands activating GABAAR subtypes located on airway smooth muscle and immune cells reduce airway hyper responsivenessAHRand inflam ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Evaluation of a Novel Connexin-Based Peptide in the Treatment of Combined Ionizing Radiation and Thermal Burn Injury
SBC: FirstString Research, Inc Topic: NIAIDPROJECT SUMMARYThe threat of a nuclear attack or disaster resulting in mass casualties is of increasing concernRadiation injury frequently occurs in combination with thermal burnsCombined radiation and thermal burn injuryCRBIresults in impaired wound healingexacerbated symptomsand synergistic increases in mortalityCountermeasures that synergistically address the complex pathophysiology of CRBI at ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
A Cloud-Based Web Application to Accelerate Targeted Covalent Drug Discovery
SBC: ComputChem LLC Topic: 400Project Summary Abstract Covalent drug discovery is gaining increasing interest and clinical successespecially for cancer and infectious diseasesAlthough old covalent drugs were discovered serendipitouslymodern covalent drug discovery takes a rational approachWhile chemical intuition and trial and error are helpfulthe discovery process can be signi cantly shortened by the knowledge of whether the ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Whole-Cell Vaccine Development for MRSA
SBC: BIOLOGICAL MIMETICS, INC. Topic: NIAIDAbstractMethicillin resistant Staphylococcus aureusMRSAis one of the leading causes of many life threatening infections such as skin and soft tissue sepsispneumoniaosteomyelitis and endocarditisDue to the growing incidence of multiple drug resistance in Saureus strains and the absence of effective new antibioticstreatment options are becoming increasingly limitedDifficulties in developing new anti ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health